Affinage

PDE6A

Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha · UniProt P16499

Length
860 aa
Mass
99.5 kDa
Annotated
2026-06-10
32 papers in source corpus 8 papers cited in narrative 8 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PDE6A encodes the alpha catalytic subunit of rod photoreceptor phosphodiesterase 6, the effector enzyme that hydrolyzes cGMP downstream of light-activated transducin in the phototransduction cascade (PMID:20940301, PMID:26188004). Its catalytic domain is enzymatically equivalent to that of PDE6B—chimeric homodimers bearing either subunit show comparable Km, kcat, and inhibitory constants for Pγ and are fully activated by rod and cone transducin-α—yet the native rod heterodimer requires markedly higher transducin to reach half-maximal activation, establishing that heterodimerization specifically tunes transducin sensitivity (PMID:20940301). PDE6A function is also required for assembly and stability of the complex: loss of PDE6A in canine frameshift mutants abolishes PDE6B and PDE6G protein along with all PDE6 enzymatic activity, and AAV-mediated PDE6A augmentation restores PDE6B levels and normalizes cGMP in vivo (PMID:18775863, PMID:29212382). Loss of PDE6A elevates photoreceptor cGMP and drives non-apoptotic rod death executed through excessive PARP and calpain activation rather than caspase, with catalytic-domain alleles (V685M, R562W, D670G) producing allele-specific cGMP accumulation and degeneration rates (PMID:26188004, PMID:27551530). Transcription is driven by a rod photoreceptor-predominant promoter (PMID:11401494). Human PDE6A loss-of-function additionally elevates systemic plasma cGMP (PMID:27820873).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2001 Medium

    Establishing where PDE6A is expressed was needed to assign it to the rod phototransduction compartment; a defined promoter localized expression predominantly to rod photoreceptors.

    Evidence Transgenic mouse reporter driven by a PDE6A upstream fragment with cross-tissue RT-PCR

    PMID:11401494

    Open questions at the time
    • Does not define the transcription factors driving rod-specific expression
    • Weak brain activity left uncharacterized
  2. 2008 High

    Whether PDE6A contributes only catalysis or also complex integrity was unknown; loss of PDE6A in a canine frameshift mutant eliminated PDE6B and PDE6G and all PDE6 activity, showing PDE6A is required for heterotetramer assembly/stability.

    Evidence Western blot and enzymatic activity assays in PDE6A-mutant dog retinas

    PMID:18775863

    Open questions at the time
    • Does not distinguish defective assembly from accelerated degradation
    • No structural account of subunit interdependence
  3. 2008 Medium

    It was unclear whether catalytic-domain point mutations affect stability as well as function; two ENU-induced missense alleles reduced both PDE6A function and PDE6B levels with allele-specific degeneration rates, revealing structure-function relationships in the catalytic domain.

    Evidence Positional cloning of ENU mutations in mice with biochemical and degeneration phenotyping

    PMID:18849587

    Open questions at the time
    • Molecular basis of allele-specific outcomes not resolved
    • No structural model linking residues to stability
  4. 2010 High

    Whether PDE6A and PDE6B catalytic subunits differ enzymatically was open; chimeric homodimers showed equivalent kinetics and Pγ inhibition, while the native heterodimer required higher transducin for activation, isolating transducin sensitivity as a heterodimerization-specific property.

    Evidence Chimeric homodimer expression in Xenopus, in vitro kinetics, Ki, and transducin activation assays

    PMID:20940301

    Open questions at the time
    • Structural basis of altered transducin sensitivity in the heterodimer unresolved
    • Role of Pγ in modulating transducin coupling not dissected
  5. 2015 Medium

    The death mechanism following PDE6A loss was undefined; multiple catalytic-domain alleles produced allele-specific cGMP accumulation with elevated calpain but not caspase activity, defining non-apoptotic execution.

    Evidence Mouse missense models with cGMP immunoassay, calpain/caspase assays, ERG and morphology

    PMID:26188004

    Open questions at the time
    • Does not establish how elevated cGMP triggers calpain
    • Compound heterozygous allelic interactions not mechanistically explained
  6. 2016 Medium

    Whether PARP causally drives the death pathway was unknown; pharmacological PARP inhibition was neuroprotective across alleles with efficacy inversely tied to mutation severity, placing PARP downstream of PDE6A dysfunction.

    Evidence PARP activity assays and PJ34 treatment of organotypic retinal explants from multiple Pde6a mutant lines

    PMID:27551530

    Open questions at the time
    • Single lab, ex vivo only
    • Ordering of PARP relative to calpain not established
  7. 2016 Low

    Whether PDE6A deficiency has systemic consequences was untested; PDE6A-deficient patients showed roughly doubled plasma cGMP, linking reduced retinal hydrolysis to elevated systemic cGMP.

    Evidence Plasma cGMP immunoassay in a small homozygous splice-site mutant cohort vs. controls

    PMID:27820873

    Open questions at the time
    • Single indirect biochemical measurement in a small cohort with no mechanistic follow-up
    • Tissue source of elevated plasma cGMP unknown
  8. 2017 Medium

    Whether restoring PDE6A could reverse the assembly and metabolic defects was open; AAV-mediated PDE6A augmentation in mutant dogs restored PDE6A and PDE6B in outer segments and normalized cGMP, opsin localization, and downstream circuitry.

    Evidence Subretinal AAV-Pde6a delivery in mutant dogs with immunohistochemistry, ERG, OCT, histology

    PMID:29212382

    Open questions at the time
    • Durability and dose-response not defined here
    • Single lab large-animal study

Open questions

Synthesis pass · forward-looking unresolved questions
  • How elevated cGMP mechanistically converges on PARP and calpain activation, and the structural basis for heterodimer-specific transducin coupling and allele-specific subunit stability, remain unresolved.
  • No structural model of the PDE6 heterotetramer in this corpus
  • Causal chain from cGMP rise to PARP/calpain not reconstituted
  • Mechanism linking specific catalytic residues to PDE6B stability unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 2 GO:0140098 catalytic activity, acting on RNA 1
Localization
GO:0005929 cilium 1
Pathway
R-HSA-5357801 Programmed Cell Death 2 R-HSA-162582 Signal Transduction 1 R-HSA-9709957 Sensory Perception 1
Partners
PDE6BPDE6G
Complex memberships
PDE6 heterotetramer (PDE6αβγ₂)

Evidence

Reading pass · 8 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 PDE6A and PDE6B catalytic subunits are enzymatically equivalent: chimeric homodimeric enzymes containing the PDE6A or PDE6B catalytic domains (EGFP-PDE6C-A and EGFP-PDE6C-B) showed similar Km (~20-23 µM), kcat (~4200-5100 s⁻¹), and Ki values for inhibition by cone- and rod-specific Pγ subunits. Both were fully activated by rod transducin-α (Gαt1) and cone transducin-α (Gαt2). In contrast, native rod PDE6 heterodimer required markedly higher concentrations of Gαt2 or Gαt1 for half-maximal activation, indicating a heterodimerization-specific difference in transducin interaction. Expression of chimeric homodimeric enzymes in transgenic Xenopus laevis, selective immunoprecipitation, in vitro enzymatic assay (Km, kcat), inhibitor Ki determination, transducin activation assays The Journal of biological chemistry High 20940301
2008 PDE6A is essential for stable expression of PDE6B and PDE6G: in a canine PDE6A frameshift mutant, Western blot showed that not only PDE6A but also PDE6B and PDE6G (the other PDE6 subunits) were absent from affected retinas, and PDE6 enzymatic activity was completely lacking, indicating PDE6A expression is required for normal assembly and/or stability of the heterotetrameric PDE6 complex. Western blot analysis of retinal PDE6 subunit levels; PDE6 enzymatic activity assay in affected vs. control retinas Investigative ophthalmology & visual science High 18775863
2008 Missense mutations in the catalytic domain of Pde6a (two ENU-induced alleles in mice) not only reduce PDE6A enzymatic function but also reduce PDE6B levels within the retina, confirming that PDE6A function is required for normal PDE6B stability in rods. The two alleles showed significantly different biochemical outcomes and rates of photoreceptor degeneration, revealing allele-specific structure-function relationships in the catalytic domain. Positional candidate cloning of ENU-induced Pde6a mutations in mice; biochemical analysis of PDE6B levels; photoreceptor degeneration phenotyping Human molecular genetics Medium 18849587
2015 Different Pde6a point mutations (V685M, R562W, D670G) in the catalytic domain cause allele-specific rates of photoreceptor degeneration associated with allele-specific levels of cGMP accumulation. In all four mutant situations (including compound heterozygous V685M/R562W), calpain activity was strongly elevated while caspase activity was not, indicating non-apoptotic cell death as the primary execution mechanism. Compound heterozygous animals showed intermediate degeneration rates consistent with allelic interactions. Mouse models with specific Pde6a missense mutations; immunohistochemistry for PDE6A expression; cGMP immunoassay; calpain and caspase activity assays; in vivo retinal function (ERG) and morphology Human molecular genetics Medium 26188004
2001 A short upstream fragment of the PDE6A gene constitutes a functional promoter that drives transcription predominantly in rod photoreceptors of the retina, with weak activity in brain but not in heart, kidney, liver, or lung, as determined in transgenic mice. Transgenic mouse lines expressing a reporter under the PDE6A upstream fragment; RT-PCR of transgene expression across tissues; in situ identification of photoreceptor-predominant expression Biochemical and biophysical research communications Medium 11401494
2016 PARP activity is excessively activated in photoreceptors of Pde6a mutant mice and is causally involved in photoreceptor cell death: PARP inhibition with PJ34 in organotypic retinal explants from Pde6a R562W, D670G, and V685M mutant mice was neuroprotective, with efficacy inversely correlated with the severity of the Pde6a mutation (D670G showing best effect). This places PARP downstream of PDE6A dysfunction in the cell death pathway. PARP activity assay in three homozygous and one compound heterozygous Pde6a mutant mouse models; organotypic retinal explant cultures treated with PARP inhibitor PJ34 at multiple time points; photoreceptor survival quantification Cell death discovery Medium 27551530
2017 AAV-mediated gene augmentation with Pde6a cDNA in Pde6a mutant dogs restores rod PDE6A protein expression in rod outer segments and is accompanied by markedly increased levels of Pde6b, confirming the dependency of PDE6B stability on PDE6A. Treated retinas showed normalization of cGMP levels, appropriate rod opsin localization, and improved bipolar cell dendrite distribution. Subretinal AAV injection in Pde6a mutant dogs; immunohistochemistry for PDE6A, PDE6B, rod opsin, cGMP; ERG; OCT; histology Human gene therapy Medium 29212382
2016 Patients homozygous for a loss-of-function splice-site mutation in PDE6A (IVS6+1G>A) have plasma cGMP levels approximately twice those of controls, indicating that reduced retinal cGMP hydrolysis by PDE6A results in elevated systemic cGMP. Immunoassay measurement of plasma cGMP in PDE6A-deficient patients vs. controls; genotyping by microarray and Sanger sequencing Investigative ophthalmology & visual science Low 27820873

Source papers

Stage 0 corpus · 32 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 New mouse models for recessive retinitis pigmentosa caused by mutations in the Pde6a gene. Human molecular genetics 63 18849587
2008 Characterization of a canine model of autosomal recessive retinitis pigmentosa due to a PDE6A mutation. Investigative ophthalmology & visual science 49 18775863
2015 Retinitis pigmentosa: impact of different Pde6a point mutations on the disease phenotype. Human molecular genetics 43 26188004
2010 Rod phosphodiesterase-6 PDE6A and PDE6B subunits are enzymatically equivalent. The Journal of biological chemistry 43 20940301
2017 Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa. Frontiers in neuroscience 40 28676737
2017 Gene Supplementation Rescues Rod Function and Preserves Photoreceptor and Retinal Morphology in Dogs, Leading the Way Toward Treating Human PDE6A-Retinitis Pigmentosa. Human gene therapy 32 29212382
2015 Splice-site mutations identified in PDE6A responsible for retinitis pigmentosa in consanguineous Pakistani families. Molecular vision 21 26321862
2017 Gene Therapy Successfully Delays Degeneration in a Mouse Model of PDE6A-Linked Retinitis Pigmentosa (RP43). Human gene therapy 20 29212391
2016 Efficacy of PARP inhibition in Pde6a mutant mouse models for retinitis pigmentosa depends on the quality and composition of individual human mutations. Cell death discovery 20 27551530
2020 Clinical Phenotype and Course of PDE6A-Associated Retinitis Pigmentosa Disease, Characterized in Preparation for a Gene Supplementation Trial. JAMA ophthalmology 17 33057649
2008 Enzymatic characteristics of two novel Myxococcus xanthus enzymes, PdeA and PdeB, displaying 3',5'- and 2',3'-cAMP phosphodiesterase, and phosphatase activities. FEBS letters 15 19114044
2000 Exclusion of the PDE6A gene for generalised progressive retinal atrophy in 11 breeds of dog. Animal genetics 14 10782214
2024 Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 13 39297417
2001 A PDE6A promoter fragment directs transcription predominantly in the photoreceptor. Biochemical and biophysical research communications 13 11401494
2006 Contribution of the cyclic nucleotide phosphodiesterases PdeA and PdeB to adaptation of Myxococcus xanthus cells to osmotic or high-temperature stress. Journal of bacteriology 12 16385075
2022 Central Visual Function and Genotype-Phenotype Correlations in PDE6A-Associated Retinitis Pigmentosa. Investigative ophthalmology & visual science 11 35533076
2022 Novel variants in PDE6A and PDE6B genes and its phenotypes in patients with retinitis pigmentosa in Chinese families. BMC ophthalmology 9 35033039
2016 Increased Plasma cGMP in a Family With Autosomal Recessive Retinitis Pigmentosa Due to Homozygous Mutations in the PDE6A Gene. Investigative ophthalmology & visual science 9 27820873
2019 Advancing Gene Therapy for PDE6A Retinitis Pigmentosa. Advances in experimental medicine and biology 8 31884596
2024 PDE6A-Associated Retinitis Pigmentosa, Clinical Characteristics, Genetics, and Natural History. Ophthalmology. Retina 7 39218074
2019 Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations. Stem cell research 7 30685614
2021 A new PDE6A missense variant p.Arg544Gln in rod-cone dystrophy. Documenta ophthalmologica. Advances in ophthalmology 6 33611760
2017 Novel PDE6A mutation in an Emirati patient with retinitis pigmentosa. Oman journal of ophthalmology 6 29118501
2021 PdeA is required for the rod shape morphology of Brucella abortus. Molecular microbiology 4 34662460
2021 Novel mutations in PDE6A and CDHR1 cause retinitis pigmentosa in Pakistani families. International journal of ophthalmology 4 34926197
2024 All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice. JCI insight 2 39499900
2021 P.arg102ser is a common Pde6a mutation causing autosomal recessive retinitis pigmentosa in Pakistani families. JPMA. The Journal of the Pakistan Medical Association 2 34057927
2000 Characterization of a cDNA encoding RP43, a CUB-domain-containing protein from the tube of Riftia pachyptila (Vestimentifera), and distribution of its transcript. The Biochemical journal 2 10947956
2019 Sildenafil Administration in Dogs Heterozygous for a Functional Null Mutation in Pde6a: Suppressed Rod-Mediated ERG Responses and Apparent Retinal Outer Nuclear Layer Thinning. Advances in experimental medicine and biology 1 31884640
2026 Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated retinitis pigmentosa: a non-randomised controlled trial. The British journal of ophthalmology 0 40825661
2024 Cortex Dictamni induces retinitis pigmentosa in zebrafish by inhibiting pde6a post-transcriptional activity via mmu-mir-6240-p3_2. Journal of ethnopharmacology 0 39716511
2018 Co-Existence of Novel PDE6A Mutations and A Recurrent RPGR Mutation: A Potential Explanation for Phenotypic Diversity in Female RPGR Mutation Carriers. Current molecular medicine 0 30289068

Missed literature

Know a paper Affinage missed for PDE6A? Flag it for the maintainers and the community.

No submissions yet.